Trial Profile
A phase Ib trial of huperzine-A in patients with treatment-resistant epilepsy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2016
Price :
$35
*
At a glance
- Drugs Huperzine A (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Pharmacodynamics
- 28 Jun 2016 Pharmacokinetic data presented at 13th EILAT Conference On New Antiepileptic Drugs, as per Biscayne Pharmaceuticals media release.
- 28 Jun 2016 Results published in Biscayne Pharmaceuticals media release.
- 17 May 2013 Top-line results were presented at AntiEplileptic Drug and Device Trials (AED) Xll meeting, according to a Insero Health media release.